Jonathan sat down with the Berkman Klein Center’s Victoria Borneman to talk about his work. During his time here, he says, he is looking for frameworks and unique ways to measure black cultural influence (and the economic impact of black creativity) in the US and around the world. Jonathan Jackson is also a Joint Fellow with the Nieman Foundation and the Berkman Klein Center for Internet & Society for 2018-2019. Blavity’s mission is to "economically and creatively support Black millennials across the African diaspora, so they can pursue the work they love, and change the world in the process." Blavity has grown immensely since their founding in 2014 - among other things, spawning five unique sites, reaching over 7 million visitors a month, and organizing a number of technology, activism, and entrepreneurship conferences. (Funded by Bayer FIDELIO-DKD number, NCT02540993.).Ĭopyright © 2020 Massachusetts Medical Society.Jonathan Jackson is a co-founder of Blavity Inc., a technology and media company for black millennials. In patients with CKD and type 2 diabetes, treatment with finerenone resulted in lower risks of CKD progression and cardiovascular events than placebo.
Jonathan berkman klein center trial#
The incidence of hyperkalemia-related discontinuation of the trial regimen was higher with finerenone than with placebo (2.3% and 0.9%, respectively). Overall, the frequency of adverse events was similar in the two groups. A key secondary outcome event occurred in 367 patients (13.0%) and 420 patients (14.8%) in the respective groups (hazard ratio, 0.86 95% CI, 0.75 to 0.99 P = 0.03). The key secondary composite outcome, also assessed in a time-to-event analysis, was death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure.ĭuring a median follow-up of 2.6 years, a primary outcome event occurred in 504 of 2833 patients (17.8%) in the finerenone group and 600 of 2841 patients (21.1%) in the placebo group (hazard ratio, 0.82 95% confidence interval, 0.73 to 0.93 P = 0.001). The primary composite outcome, assessed in a time-to-event analysis, was kidney failure, a sustained decrease of at least 40% in the eGFR from baseline, or death from renal causes.
All the patients were treated with renin-angiotensin system blockade that had been adjusted before randomization to the maximum dose on the manufacturer's label that did not cause unacceptable side effects. Eligible patients had a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of 30 to less than 300, an estimated glomerular filtration rate (eGFR) of 25 to less than 60 ml per minute per 1.73 m 2 of body-surface area, and diabetic retinopathy, or they had a urinary albumin-to-creatinine ratio of 300 to 5000 and an eGFR of 25 to less than 75 ml per minute per 1.73 m 2.
In this double-blind trial, we randomly assigned 5734 patients with CKD and type 2 diabetes in a 1:1 ratio to receive finerenone or placebo. Hendrickson will help lead the center and shape its next generation of education, research, and engagement on technology and society, connecting it to new communities and collaborators. The Berkman Klein Center for Internet & Society at Harvard University has announced the appointment of Susan Hendrickson ’93 as its new executive director. However, its long-term effects on kidney and cardiovascular outcomes are unknown. Berkman Klein Center welcomes Susan Hendrickson as executive director. Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced albuminuria in short-term trials involving patients with chronic kidney disease (CKD) and type 2 diabetes.